Evidence map›Paper›PMID 29449583›Full record

ArticleScientific reports2018

Mesoporous silica nanocarriers encapsulated antimalarials with high therapeutic performance.

Saliu Alao Amolegbe, Yui Hirano, Joseph Oluwatope Adebayo, Olusegun George Ademowo, Elizabeth Abidemi Balogun, Joshua Ayoola Obaleye, Antoniana Ursine Krettli, Chengzhong Yu, Shinya Hayami

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. AttenuatedFrontiers in immunology · 2020
    Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Saliu Alao AmolegbeDepartment of Chemistry, College of Physical Sciences, Federal University of Agriculture, Abeokuta (FUNAAB) PMB, Abeokuta, 2240, Nigeria.
Yui HiranoDepartment of Chemistry, Graduate School of Science and Technology, Kumamoto University, 2-39-1 Kurokami, Chuo-ku, Kumamoto, 860-8555, Japan.
Joseph Oluwatope AdebayoDepartment of Biochemistry, Faculty of Life Sciences, University of Ilorin, PMB 1515, Ilorin, Kwara State, Nigeria.
Olusegun George AdemowoInstitute for Advanced Medical Research and Training (IAMRAT) College of Medicine University College Hospital, University of Ibadan, Ibadan, Nigeria.
Elizabeth Abidemi BalogunDepartment of Biochemistry, Faculty of Life Sciences, University of Ilorin, PMB 1515, Ilorin, Kwara State, Nigeria. ea_balogun@yahoo.com.
Joshua Ayoola ObaleyeDepartment of Chemistry, Faculty of Physical Sciences, University of Ilorin, PMB 1515, Ilorin, Kwara State, Nigeria.
Antoniana Ursine KrettliLaboratorio de Malaria, Centro de Pesquisas Rene Rachou, FIOCRUZ, Belo Horizonte, 30130-100 MG, Brazil.
Chengzhong YuAustralian Institute for Bioengineering and Nanotechnology, The University of Queensland, Queensland, QLD, 4072, Australia. c.yu@uq.edu.au.
Shinya HayamiDepartment of Chemistry, Graduate School of Science and Technology, Kumamoto University, 2-39-1 Kurokami, Chuo-ku, Kumamoto, 860-8555, Japan. hayami@sci.kumamoto-u.ac.jp.ORCID 0000-0001-8392-2382

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of nanocarriers in drug delivery is a breakeven research and has received a clarion call in biomedicine globally. Herein, two newly nano-biomaterials: MCM-41 encapsulated quinine (MCM-41 ⊃ QN) (1) and 3-phenylpropyl silane functionalized MCM-41 loaded QN (pMCM-41 ⊃ QN) (2) were synthesized and well characterized. 1 and 2 along with our two already reported nano-antimalarial drugs (MCM-41 ⊃ ATS) (3) and 3-aminopropyl silane functionalized MCM-41 contained ATS (aMCM-41 ⊃ ATS) (4) were screened in vitro for their activity against P. falciparium W2 strain, cytotoxicity against BGM cells and in vivo for their activity against Plasmodium bergheiNK65. 1 has the highest antimalarial activity in vivo against P. berghei NK65, (ED

Indexed as

AntimalarialsDrug Delivery SystemsErythrocytesInhibitory Concentration 50MalariaNanoparticlesPlasmodium bergheiPlasmodium falciparumQuinineSilicon DioxideAntimalarialsMCM-41QuinineSilicon Dioxide

Identifiers

PMID29449583
PMCPMC5814455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.